Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effectiveness and safety of a new treatment for individuals with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The treatment being tested is a medication known by its code name, JNJ-77242113, which is taken as a film-coated tablet. The study will compare this medication to a placebo to determine how well it works in improving the symptoms of plaque psoriasis.

The purpose of the study is to evaluate how effective JNJ-77242113 is in treating people with moderate to severe plaque psoriasis. Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will involve a period where participants take the medication, followed by a withdrawal phase, and then a possible retreatment phase. This approach helps researchers understand the medication's long-term effects and how it performs when treatment is paused and then restarted.

Throughout the study, participants will be monitored to assess the improvement in their psoriasis symptoms. The study aims to see if participants achieve a significant reduction in the severity of their skin condition by the end of the treatment period. The trial is designed to ensure that the medication is both effective and safe for those who take it. Participants will be closely observed by medical professionals to track any changes in their condition and to ensure their well-being during the study.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to receive either the study medication, JNJ-77242113, or a placebo. A placebo is a tablet that looks like the medication but does not contain the active ingredient.

    The study is designed to be double-blind, meaning neither you nor the study team will know which treatment you are receiving. This helps ensure the results are unbiased.

  2. Step 2

    Initial treatment phase

    During the initial treatment phase, you will take the assigned tablet orally. The dosage and frequency will be provided by the study team.

    This phase lasts for 16 weeks. The goal is to evaluate the effectiveness of the treatment in reducing the symptoms of moderate to severe plaque psoriasis.

  3. Step 3

    Evaluation at week 16

    At the end of week 16, your condition will be evaluated. The primary goal is to see if there is a significant improvement in your skin condition.

    The evaluation will include checking if your skin has cleared significantly or if there is a noticeable reduction in the severity of your psoriasis.

  4. Step 4

    Randomized withdrawal phase

    If you respond well to the treatment, you may enter a randomized withdrawal phase. This means you might continue with the treatment or switch to a placebo without knowing.

    This phase helps determine if the treatment's effects are sustained over time without continuous medication.

  5. Step 5

    Retreatment phase

    If your condition worsens during the withdrawal phase, you may be eligible for retreatment with JNJ-77242113.

    The study team will guide you through this process and monitor your response to the retreatment.

  6. Step 6

    End of study

    At the end of the study, you will undergo a final evaluation to assess the overall effectiveness and safety of the treatment.

    The study team will discuss the results with you and provide any necessary follow-up care or recommendations.

Who can join the trial?

5 criteria

  • Must be at least 12 years old at the time of the screening visit.
  • Must have a diagnosis of plaque psoriasis (a skin condition) for at least 26 weeks before the first study treatment. This can be with or without psoriatic arthritis (a type of arthritis that affects some people with psoriasis).
  • Must have 10% or more of their body surface area (BSA) affected by psoriasis at screening and at the start of the study. BSA is a way to measure how much of the body is affected.
  • Must have a PASI score of 12 or higher at screening and at the start of the study. PASI (Psoriasis Area and Severity Index) is a tool used to measure the severity and extent of psoriasis.
  • Must have an IGA score of 3 or higher at screening and at the start of the study. IGA (Investigator's Global Assessment) is a scale used to assess the overall severity of psoriasis.

Who cannot join the trial?

8 criteria

  • Patients with any other skin conditions that might interfere with the study results.
  • Patients who have had a recent infection or are currently experiencing an infection.
  • Patients who have received any other treatment for psoriasis within a certain period before the study.
  • Patients with a history of certain serious diseases, such as cancer or heart disease.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial recently.
  • Patients with a known allergy to any of the study medications.
  • Patients who are unable to follow the study procedures or attend the required visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

JNJ-77242113 is a medication being studied for its potential to help people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. This medication is designed to target specific parts of the immune system that are thought to play a role in causing these skin changes. By doing so, it may help reduce the symptoms of psoriasis, such as redness and scaling, and improve the overall appearance of the skin. The study aims to see how well this medication works and how safe it is for people with this condition.

What is already known about the treatment

JNJ-77242113 – JNJ-77242113 is administered in a form that is suitable for treating moderate to severe plaque psoriasis, a condition characterized by red, scaly skin patches. Currently, this medication is being studied in clinical trials to assess its effectiveness and safety for this specific skin condition. The main therapeutic indication for JNJ-77242113 is to alleviate the symptoms of moderate to severe plaque psoriasis. At the molecular level, it works by targeting specific pathways in the immune system that contribute to the inflammation and rapid skin cell growth seen in psoriasis. This medication falls under the pharmacological classification of immunomodulators, which are drugs that help regulate or normalize the immune system.

Investigated diseases

Plaque Psoriasis – Plaque psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells, leading to the formation of thick, red, scaly patches on the skin. These patches, known as plaques, often appear on the elbows, knees, scalp, and lower back, but they can occur anywhere on the body. The disease progresses through cycles, with periods of increased activity (flare-ups) followed by periods of remission. During flare-ups, the plaques can become itchy, painful, and may crack or bleed. The exact cause of plaque psoriasis is not fully understood, but it involves an overactive immune response that accelerates skin cell production. Environmental factors, stress, and certain triggers can exacerbate the condition, leading to more frequent or severe flare-ups.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-505120-59-00Protocol code77242113PSO3001Estimated enrolment600 patientsSponsorJanssen - Cilag International

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.